| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a74935159a0a871dd85e00c138f7fe6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7b72691b61448140b9a080282c2ccf0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate |
2017-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c1f20bbc0b5764f6a8a534d1fb3b12e |
| publicationDate |
2018-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180111077-A |
| titleOfInvention |
Composition for treating cancer drug resistance including the combination of aspirin and multikinase inhibitor |
| abstract |
More particularly, the present invention relates to a pharmaceutical composition for preventing or treating cancer in a platinum-based anticancer drug comprising aspirin and a polynuclear kinase inhibitor as an active ingredient, And a pharmaceutical composition for promoting the anti-cancer effect of a platinum-based anticancer agent. The low dose combination administration method of the aspirin and the multi-kinase inhibitor of the present invention overcomes the platinum-based anticancer drug resistance without side effects and significantly improves the cytotoxicity of the platinum-based anticancer drug in patients suffering from platinum-based anticancer drug resistance, Lt; / RTI > |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021032212-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115105599-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023022520-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111632066-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110934879-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110934879-B |
| priorityDate |
2017-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |